MRVL:NASDAQMarvell Technology, Inc. Analysis
Data as of 2026-05-23 - not real-time
$196.33
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Marvell (MRVL) is trading at $196.33, well above its DCF‑derived fair value of $50.13, implying a ~‑24% downside from intrinsic estimates. The stock sits comfortably above its 20‑day ($171.23), 50‑day ($137.50) and 200‑day ($95.91) moving averages, with a bullish MACD crossover and a high RSI of 71, suggesting strong upward momentum but also a potential overbought condition. Revenue is expanding at a robust 22% YoY, driven by a 51% gross margin and a 32.5% profit margin, while cash on hand ($2.64 B) comfortably exceeds dividend needs, reflected in a modest 0.12% yield and a low 7.8% payout ratio.
Recent material news – notably the acquisition of Polariton Technologies to boost optical‑photonics capabilities for AI‑driven data centers and upbeat analyst upgrades reaffirming a "Buy" stance – reinforces the growth narrative. However, the stock’s valuation metrics (PE 64× vs industry 39×, PB 11.6×) and high beta (2.33) underscore significant price risk, especially given the 30‑day volatility of 58% and a max drawdown of 26%.
Recent material news – notably the acquisition of Polariton Technologies to boost optical‑photonics capabilities for AI‑driven data centers and upbeat analyst upgrades reaffirming a "Buy" stance – reinforces the growth narrative. However, the stock’s valuation metrics (PE 64× vs industry 39×, PB 11.6×) and high beta (2.33) underscore significant price risk, especially given the 30‑day volatility of 58% and a max drawdown of 26%.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 7/10
Key Factors
- Bullish technical setup (price above all SMAs, MACD bullish)
- RSI indicating near‑overbought conditions
- Recent acquisition bolstering AI‑infra positioning
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Strong revenue growth and high margins
- Integration of Polariton's photonics to capture AI data‑center demand
- Analyst consensus of strong‑buy and favorable forward EPS guidance
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- Fundamentally solid cash flow but elevated valuation multiples
- High beta and volatility that may temper price appreciation
- Sustained dividend with low payout ratio supporting shareholder returns
Key Metrics & Analysis
Financial Health
Revenue Growth22.10%
Profit Margin32.58%
P/E Ratio64.2
ROE19.25%
ROA3.94%
Debt/Equity33.48
P/B Ratio11.6
Op. Cash Flow$1.8B
Free Cash Flow$1.4B
Industry P/E39.5
Technical Analysis
TrendBullish
RSI71.2
Support$146.85
Resistance$198.40
MA 20$171.23
MA 50$137.50
MA 200$95.91
MACDBullish
VolumeIncreasing
Fear & Greed Index91.61
Valuation
Fair Value$50.13
Target Price$149.93
Upside/Downside-23.64%
GradeOvervalued
TypeGrowth
Dividend Yield0.12%
Risk Assessment
Beta2.33
Volatility58.34%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.